Allogene Therapeutics, Inc. (ALLO)
After hours:
| Previous close | 10.62 |
| Open | 10.55 |
| Bid | 10.50 x 2200 |
| Ask | 12.23 x 3000 |
| Day's range | 10.55 - 11.55 |
| 52-week range | 6.43 - 26.21 |
| Volume | |
| Avg. volume | 1,655,474 |
| Market cap | 1.565B |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time. The webcast will be posted to the Company's website at www.allogene.com under the Investors tab in
- GlobeNewswire
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2 Protocol and Chemistry Manufacturing and Controls (CMC) for Use of ALLO-501A Manufactured from Cell Forge 1 (CF1)CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T™ Products Annually at Scale CF1 Earned a LEED® Interior Design and Construction Gold Designation from the U.S Green Bu
- GlobeNewswire
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in three upcoming investor conferences. 42nd Annual Canaccord Genuity Growth ConferenceThursday, August 11, 2022Noon PT/3:00PM ET H.C. Wainwright 24th Annual Global Investment ConferenceMonday, September 12, 2022Presenta
